Shu Jin

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim et al. · JAMA Oncology · 2021 · 289 citations · Full text

Medicine, Oncology, Pharmacology +15

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial

Gregory J. Riely, Joel W. Neal, D. Ross Camidge et al. · Cancer Discovery · 2021 · 222 citations · Full text

Medicine, Oncology, Pharmacology +16

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations

Sai‐Hong Ignatius Ou, Huamao Mark Lin, Jin‐Liern Hong et al. · JTO Clinical and Research Reports · 2023 · 49 citations · Full text

Medicine, Oncology, Pharmacology +9

Mobocertinib (TAK-788) in <i>EGFR</i> exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.

Suresh S. Ramalingam, Caicun Zhou, Tae Min Kim et al. · Journal of Clinical Oncology · 2021 · 30 citations

Medicine, Oncology, Pharmacotherapy +16

OA04.03 Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations

C. Zhou, Suresh S. Ramalingam, B. Li et al. · Journal of Thoracic Oncology · 2021 · 28 citations · Full text

Medicine, Oncology, Pharmacology +15